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Abstract
Glioblastomas and brain metastases (BM) of solid tumours are the most common 
central nervous system neoplasms associated with very unfavourable prognosis. In 
this study, we report the association of prostate-specific membrane antigen (PSMA) 
with various clinical parameters in a large cohort of primary and secondary brain 
tumours. A tissue microarray containing 371 cases of ascending grades of gliomas 
pertaining to astrocytic origin and samples of 52 cases of primary lung carcinomas 
with matching BM with follow-up time accounting to 10.4 years was evaluated for 
PSMA expression using immunohistochemistry. In addition, PSMA expression was 
studied in BM arising from melanomas and breast carcinomas. Neovascular expres-
sion of PSMA was evident alongside with high expression in the proliferating mi-
crovasculature of glioblastomas when compared to the tumour cell expression. This 
result correlated with the results obtained from the in silico (cancer genome data-
bases) analyses. In gliomas, only the vascular expression of PSMA associated with 
poor overall survival but not the tumour cell expression. In the matched primary lung 
cancers and their BM (n = 52), vascular PSMA expression in primary tumours as-
sociated with significantly accelerated metastatic dissemination to the brain with a 
tendency towards poor overall survival. Taken together, we report that the vascular 
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1  | INTRODUC TION
Gliomas, neoplasms of glial cell origin, constitute approximately 30% 
of all nervous system tumours and 80% of all malignant brain tu-
mours.1 Glioblastoma, a grade IV astrocytoma, is the most frequent, 
aggressive and lethal glioma.2 Glioblastomas harbour a dense abnor-
mal vasculature, display large hypoxic and necrotic areas and con-
tain extensively proliferating tumour cells with the intrinsic ability to 
disseminate and colonize the organ far beyond the principal tumour 
mass. The current standard of care comprising surgery followed by 
radio- and chemotherapy provides only a modest improvement in 
the progression-free and overall survival, and patient prognosis re-
mains dismal.3,4 Brain metastases (BM) of solid tumours are the most 
frequent intracranial tumours and about 10-fold more common than 
primary brain tumours.5 BMs are associated with severe neurolog-
ical symptoms and abysmal prognosis compared with other meta-
static sites.6 The primary tumours most often responsible for BM 
are melanomas (5%-20%), and lung (36%-64%) and breast cancers 
(15%-25%).7
Prostate-specific membrane antigen (hereon referred to as 
PSMA) also known as glutamate carboxypeptidase II (GCP II), 
N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALDase I) or 
N-acetyl-aspartyl-glutamate (NAAG) peptidase is a transmembrane 
glycoprotein encoded by the FOLH1 gene. Until today, only two 
well-defined physiological roles of PSMA are known: the folate-hy-
drolysing activity in the small intestine and the NAAG-hydrolysing 
activity in the nervous system.8,9 PSMA is expressed in tumour cells 
of almost all prostate cancers, and its increased expression is asso-
ciated with tumour aggressiveness, metastasis and recurrence.10,11 
Numerous studies have shown that the normal vasculature is de-
void of PSMA expression, while tumour neovasculature often shows 
high PSMA expression.12-14 Moreover, PSMA expression has been 
reported in benign gliomas (grade I), malignant glioblastomas (grade 
IV) and breast cancer BM with very limited number of patients.15 
Conway et al16 showed that PSMA expression is critical during an-
giogenesis as PSMA null mice were unable to mount a pathological 
angiogenic response.16 In addition, Grant et al reported that PSMA-
regulated angiogenesis was independent of VEGF by using a mouse 
model of oxygen-induced retinopathy.17
Our study is in line with the previous reports about PSMA ex-
pression in the tumour neovasculature. However, we accompany our 
immunohistochemical study with the PSMA mRNA level expression 
analyses in large genetic data sets. We report higher PSMA expres-
sion in glioblastomas compared to lower-grade gliomas. For the first 
time, we report PSMA expression in the proliferating microvascu-
lature (PM) of glioblastomas, which is one of the histopathological 
features that differentiate glioblastoma from the lower-grade gli-
omas. Moreover, only the vascular PSMA expression in gliomas is 
associated with poor overall survival. We also had an exceptional 
opportunity to screen rarely available specimens of the matched pri-
mary lung cancers and their BM as well as samples from melanoma 
and breast cancer BM. Importantly, PSMA expression in the primary 
lung tumour vasculature is associated with significantly accelerated 
metastatic dissemination to the brain with a tendency towards poor 
overall survival. Overall, the large sample size along with the in sil-
ico data analyses provides more comprehensive view on the role of 
PSMA compared with prior studies involving much smaller patient 
cohorts.
2  | MATERIAL S AND METHODS
2.1 | Patient material
2.1.1 | Gliomas
The ethical committee of Tampere University Hospital and the 
National Authority for Medicolegal Affairs in Finland approved the 
usage of tumour tissue array and the study design. The tumour sam-
ples were collected from the patients who underwent surgery at the 
Tampere University Hospital during the years 1983-2009. The as-
trocytoma specimens were initially fixed in 4% phosphate-buffered 
formaldehyde and then processed into paraffin blocks. One histo-
logically representative tumour region was selected from each spec-
imen. From the selected regions, 0.6-mm tissue cores were mounted 
into tissue microarray (TMA) blocks.18 Our tumour series included 
371 gliomas of astrocytic origin ranging from 41 (11.05%) grade I 
pilocytic astrocytomas, 46 (12.39%) grade II diffuse astrocytomas, 
25 (6.73%) grade III anaplastic astrocytomas and 259 (69.81%) grade 
IV glioblastomas (Table 1) based on the diagnosis at the time of the 
surgery. Of these 371 gliomas, 288 were primary and 83 were recur-
rent tumours from 174 men and 114 women (Table 1).
2.1.2 | Primary lung tumours and BMs
Samples of surgically resected, paired primary lung carcinomas and 
their associated BMs from 52 patients, as well as breast carcinoma 
BMs from 18 patients and melanoma BMs from 19 patients, were 
analysed in this study. Additionally, TMAs consisted of primary lung 
carcinomas from 3 patients and lung BMs from 4 patients apart from 
the paired samples. Permissions to use the archived tissues have 
expression of PSMA in the primary and secondary brain tumours globally associates 
with the malignant progression and poor outcome of the patients.
K E Y W O R D S
brain metastasis, glioblastoma, proliferating microvasculature, PSMA
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been obtained from the Local Ethical Committee of the Semmelweis 
University (Budapest, Hungary) (TUKEB-1552012, TUKEB-5102013 
and TUKEB-862015), and the study was performed in compli-
ance with the Declaration of Helsinki. The samples were fixed in 
10% neutral-buffered formalin, dehydrated and cleared in increas-
ing concentration of ethanol and xylol before embedding into 
IHC-grade paraffin. For the TMA, haematoxylin and eosin-stained 
sections were used to define the tumour areas and three repre-
sentative 2-mm cores were obtained from each case and inserted 
in a grid pattern into a recipient paraffin block using a tissue arrayer 
(3DHISTECH, Budapest, Hungary).
2.2 | Immunohistochemistry
Specificity of the anti-PSMA antibody was verified using samples 
from normal human liver and kidney that showed labelling of hepat-
ocytes and renal tubules as anticipated (Figure S1A,B). In addition, 
PSMA protein level was verified using extracts from the LnCAP 
(PSMA-positive) and PC3 (PSMA-negative) prostate cancer cell lines 
(Figure S1C) to confirm the detection of the expected PSMA protein 
band (84 kD).
The PSMA and CD31 expression was detected from the sections 
by using the TSA Kit (PerkinElmer) according to the manufacturer's 
instructions. Tumour samples were deparaffinized by immersing the 
slides in xylene and rehydrated with graded ethanol (100%-70%) and 
water. Briefly, the antigen was retrieved with heat treatment in ci-
trate buffer (1.8 mmol/L citric acid, 8.2 mmol/L sodium citrate, pH 
5.0). The endogenous peroxidase activity was irreversibly inactivated 
by incubating the sections with 3% H2O2-MetOH for 10 minutes and 
blocked with TNB buffer (0.1 mol/L Tris-HCl (pH 7.5), 0.15M NaCl 
and 0.5% blocking reagent from TSA kit) for 30 minutes. The pri-
mary antibody, rabbit anti-human mAb for PSMA (ab133579, Abcam, 
4 µg/mL) and mouse anti-human CD31 (M0823, DAKO), was applied 
overnight at 4°C. After primary antibody incubation and washes 
with TNT (Tris/NaCl/Tween-20) buffer, the sections were incubated 
with the biotinylated secondary antibody (goat anti-rabbit (E0432) 
and goat antimouse (E0433), Dako) for 60 minutes. The signal was 
amplified by using the SA-HRP and biotinylated tyramide and finally 
visualized using the AEC (0.95M 3-amino-9-ethylcarbazole, 6% N,N 
dimethylformamide, 94% sodium acetate, 0.01% H2O2). The sections 
were counterstained with Mayer's haematoxylin.
2.3 | Evaluation of immunostaining and 
statistical analysis
Overall analysis was performed for all patients whose tumour tissue 
was available for immunohistochemistry. PSMA-stained sections 
were scanned using the 3DHISTECH Pannoramic 250 FLASH II digi-
tal slide scanner at an absolute magnification of 20×. The evaluation 
of the scanned sections was performed blinded to the clinical data. 
The PSMA staining in the TMAs was scored as negative (0), weakly 
positive (1), moderately positive (2) or highly positive (3) and then 
grouped as negative (0) or positive (1-3 = 1) for further statistical 
analysis (Figure S2). We graded separately the vascular and cellular 
expression of PSMA and associated it with the clinical and molecu-
lar pathological parameters. The samples in the TMA that lacked 
vascular structures were marked as empty and excluded from the 
analysis. An experienced neuropathologist (HH) verified the PSMA 
Astrocytoma Grade I Grade II Grade III Grade IV Total
No. of patientsa  41 46 25 259 371
Primary 33 34 16 205 288
Residual
Second 7 11 6 43 67
Third-sixth 1 1 3 11 16
Sex (n)b 
Male 20 24 8 122 174
Female 13 10 8 83 114
Age (y)b 
Median 11 40 39.50 62.00 —
Mean ± SD 18.4 ± 16.7 42.8 ± 17.5 42.2 ± 14.5 61.4 ± 11.0 —
Minimum 1 12 23 4 —
Maximum 57 83 81 84 —
Follow-up
End survivors 
(n)
26 13 5 7 51
5-y survival (%) 81.3 38.2 31.3 3.4 17.8
aIncludes primary and secondary tumours. 
bIncludes only primary tumours. 
TA B L E  1   Clinicopathologic features of 
astrocytomas
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expression in the tumour cells and in the vasculature. Overall survival 
was calculated from the date of primary tumour diagnosis to the date 
of death, censoring the patients who were alive at the end of the 
follow-up period, and the progression-free survival from the date of 
diagnosis to the date of tumour progression or death, censoring pa-
tients without detected progression or death. Brain metastasis-free 
survival was calculated from the date of primary tumour diagnosis 
to the date of brain surgery. Brain metastasis was reported in all pa-
tients in the cohort. The statistical analysis was performed using the 
IBM SPSS statistics 21.0 software for Windows. Chi-squared and 
non-parametric tests were used to analyse the associations between 
PSMA expression and various clinical and molecular pathological pa-
rameters. Overall, progression-free and brain metastasis-free sur-
vival were analysed using the Kaplan-Meier and survival between 
the groups was compared using the log-rank and Breslow tests. The 
overall survival in primary lung carcinomas was analysed in 55 pa-
tients including both the paired (n = 52) and unpaired (n = 3) samples. 
The analysis of time to metastatic dissemination was performed 
using only the paired (n = 52) patient samples. A P-value of <0.05 
was considered significant. Statistical analyses for public data sets 
were performed using the R version 3.2.2.
2.4 | Tumour data sets
The clinical data and level 3 mRNA microarray data (Agilent 244K 
The Cancer Genome Atlas [TCGA] Custom 1-2) of primary glio-
blastoma (GBM) samples were downloaded from the NCI Genomic 
Data Commons. Combining multiple samples from the same patient 
using median and removing samples without clinical data resulted in 
567 samples. FPKM values for the GBM anatomic structures (122 
samples) and sample information were downloaded from the Ivy 
GAP website (http://gliob lasto ma.allen insti tute.org/).19 Data were 
log2-transformed. We have used TCGA nomenclature for the glio-
blastoma terminology.
3  | RESULTS
3.1 | PSMA is highly expressed in the hyperplastic 
proliferating microvasculature of grade IV gliomas
To evaluate the PSMA protein expression in human glioma samples, 
TMAs containing 371 grade I-IV gliomas were stained using the 
anti-PSMA antibody. Vascular expression of PSMA (Figure 1A,C,E) 
was validated by visualizing the blood vessels using an anti-CD31 
antibody (Figure 1B,D,F). We grouped the samples as positive (1) 
or negative (0). For the vascular expression, we excluded the sam-
ples that did not show any vascular structures in the TMA samples. 
PSMA expression was most frequently detected in the vasculature 
of glioblastomas (30.8%, 74/166) (P = 0.044) (Table 2) highlighting 
the distinct angiogenic feature of glioblastomas. The less angio-
genic, lower-grade gliomas showed reduced PSMA expression in 
their vasculature: grade III (14.2%, 3/18), grade II (17.9%, 7/32) and 
grade I (15%, 6/34) (Table 2). We next analysed PSMA expression in 
tumour cells to address whether an association exists between the 
vascular and cellular expression of PSMA. About 1/3 of the grade 
I (31.7%, 13/28) and II tumours (32.6%, 15/31) showed PSMA ex-
pression in tumour cells, whereas 56% (14/11) of grade III and 44.7% 
(116/143) of grade IV gliomas (Table 2) expressed PSMA in tumour 
cells. However, the overall expression in tumour cells was lower than 
the one detected in the tumour blood vessels.
F I G U R E  1   Expression of the 
prostate-specific membrane antigen 
(PSMA) in gliomas. PSMA expression 
in the vasculature (A, C, E) of grade IV 
glioblastoma was validated by staining the 
blood vessels using anti-CD31 antibody 
(B, D, E) in a subsequent tissue section. 
Arrows point the high PSMA (A, C) and 
CD31 expression (B, D) in the hyperplastic 
proliferating microvasculature. A and 
B, magnification 10x; C and D, higher 
magnification of the boxed area in A and 
B; E and F, high magnification micrograph. 
Scale bar = 100 μm
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One of the diagnostic histopathological features that differen-
tiate glioblastoma from the lower-grade gliomas is the presence of 
proliferating hyperplastic microvasculature that appears as tufted 
glomeruloid bodies and exists adjacent to the necrotic foci with bor-
dering pseudopalisading cells. The glomeruloid tuft-like structures 
in certain tumour samples in the TMAs were positive for PSMA. 
Therefore, we analysed the entire tumour block of two grade IV 
glioblastomas that were highly positive for the vascular expres-
sion of PSMA. This analysis confirmed that not the pre-existing 
mature vessels, but the proliferating hyperplastic microvasculature 
TA B L E  2   Histological classification of astrocytic tumours based on PSMA expression
Tumour grade  
Pilocytic
grade I
Diffuse
grade II
Anaplastic
grade III
Glioblastoma
grade IV Total
P-value
chi-square
PSMA (+/−) Vascular 15% (6/34) 17.9% (7/32) 14.2% (3/18) 30.8% (74/166) 26.47%
(90/250)
.044
PSMA (+/−) Tumour cells 31.7% (13/28) 32.6% (15/31) 56% (14/11) 44.7% (116/143) 42.5% (158/213) .102
Abbreviation: PSMA, prostate-specific membrane antigen.
F I G U R E  2   Analysis of PSMA/FOLH1 
mRNA expression using the TCGA 
database and association of PSMA/FOLH1 
expression with patient survival in 
gliomas. A, Expression of PSMA/FOLH1 
was lower in the classical subtype (CL) 
compared to the other subtypes in 
the TCGA analysis (P < 0.01). B, The 
proliferating microvasculature (PM) 
showed the highest and the cellular 
pseudopalisades (CP) the lowest PSMA 
expression when compared to other 
groups in the Ivy GAP database analysis 
(P < 0.001). C, Integrin β1 is specifically 
up-regulated in the proliferating 
microvasculature (PM) in the Ivy 
GAP database analysis similar to the 
PSMA/FOLH1 expression. D, The vascular 
PSMA expression is associated with poor 
overall survival of the patients (n = 263, 
P = 0.032). E, No significant association 
with the overall survival was observed 
when the tumour cell expression of PSMA 
protein was analysed (n = 287, P = 0.223). 
F, No significant association with the 
overall survival was observed when PSMA 
mRNA expression was analysed using 
the TCGA database (n = 567, P = 0.544). 
PSMA, prostate-specific membrane 
antigen; TCGA, The Cancer Genome Atlas
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expressed high levels of both PSMA (Figure 1A,C,E) and a vascular 
marker CD31 (Figure 1B,D,F). To study PSMA (FOLH1) expression in 
the glioblastoma subtypes, we analysed 567 mRNA microarray sam-
ples using the TCGA GBM data set (see Materials and Methods, and 
nomenclature from the TCGA). When we compared the expression 
of PSMA between the different subtypes, we observed decreased 
PSMA expression in the classical (CL) subtype compared to the other 
subtypes (P < 0.01, Wilcoxon rank-sum test) (Figure 2A). Therefore, 
decreased PSMA expression might be associated with the classical 
subtype.
Next, we analysed PSMA (FOLH1) expression using the Ivy GAP 
RNA-Seq data set (http://gliob lasto ma.allen insti tute.org/) that, in 
contrast to other cancer genome data sets, shows the individual gene 
expression profiles for the different anatomic structures, such as 
TA B L E  3   Overall survival in gliomas based on PSMA expression
Tumour Features Function
PSMA (+)
Total/censored
PSMA (−)
Total/censored
Total
Total/censored
P-Value
Log-rank
Gliomas
Grade (I-IV)
Vascular OS 71/7 192/39 263/46 .032
Tumour cells OS 115/18 172/33 287/51 .223
Abbreviations: OS, overall survival; PSMA, prostate-specific membrane antigen.
F I G U R E  3   PSMA expression in the 
brain metastases of breast carcinomas 
and melanomas as well as in primary 
lung carcinomas and their associated 
metastases. A. PSMA is highly expressed 
in the vasculature of the brain metastases 
of breast adenocarcinoma (A) and 
invasive ductal carcinoma (C) as well as 
in the vasculature of melanoma brain 
metastases (B, D). E, G and I, Vasculature 
of the primary lung carcinomas of 
different histological subtype such as 
adenocarcinoma (E), small-cell lung 
carcinoma (G) and squamous cell 
carcinoma (I) was highly positivity for 
PSMA. F, H and J, The brain metastases 
of the lung adenocarcinoma (F), small-
cell lung carcinoma (H) and squamous 
cell carcinoma (J) also expressed PSMA 
in their vasculature. There was a pattern 
of cellular pseudopalisades (arrows in J) 
closely surrounded by the PSMA-positive 
vasculature similar to the one seen in 
glioblastomas. Scale bar = 100 μm. PSMA, 
prostate-specific membrane antigen
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leading edge (LE), infiltrating tumour (IT), cellular tumour (CT), PM and 
cellular pseudopalisades (CP), which were isolated by using the laser 
microdissection.19 Consistent with our findings, PM showed the high-
est (P < 0.001, Wilcoxon rank-sum test) and the CP the lowest PSMA 
expression when compared to other groups (P < 0.001, Wilcoxon rank-
sum test) (Figure 2B). As it has been reported that PSMA is involved 
in angiogenesis by activating the laminin-mediated integrin β1 (ITGB1) 
signalling,16 we analysed the ITGB1 expression using the Ivy GAP. 
Also, in this data set, ITGB1was up-regulated in the PM when com-
pared with all the other anatomic structures (Figure 2C) (P < 0.001).
3.2 | Vascular expression of PSMA associates with 
poor prognosis in gliomas
We next analysed the association of PSMA protein level with patient 
survival in our TMA material using the log-rank test. The vascular 
PSMA expression was associated with poor overall survival of pa-
tients (n = 263) (P = 0.032, log-rank test) (Figure 2D and Table 3), 
whereas no association with survival of PSMA in tumour cells was 
detected (n = 287) (P = 0.223, log-rank test) (Figure 2E and Table 3). 
We also analysed the association of PSMA (FOLH1) expression with 
patient survival using the TCGA GBM data set (n = 567 mRNA mi-
croarray samples), which contains transcriptome data of the whole 
tumour bulk comprising mostly of tumour cells. No association with 
patient survival was observed when patients were separated based 
on the PSMA (FOLH1) expression as the highest 25% compared to 
the lowest 25% (P = 0.544, log-rank test) (Figure 2F). Thus, PSMA 
expression in the vasculature of gliomas associates with poor over-
all survival while no significant association with patient survival of 
PSMA expression in tumour cells was detected.
3.3 | PSMA expression in the secondary 
brain tumours
Extending our study, we analysed PSMA expression in the BMs 
of breast and lung carcinomas and melanomas. Of the whole tis-
sue sections analysed, all 18/18 breast cancer BM samples (breast 
adenocarcinoma, n = 1; infiltrative duct carcinomas, n = 17) 
(Figure 3A,C) and 18/19 melanoma BMs (Figure 3B,D) expressed 
PSMA in their vasculature. Next, we compared PSMA expression 
in the primary lung tumours and their associated BMs and scored 
separately the vascular and tumour cell expression. The primary 
lung carcinoma samples in our tissue array were of various his-
tological types containing (a) non-small-cell lung cancers such as 
adenocarcinomas and squamous cell carcinomas and (b) small-cell 
lung carcinomas (SCLC). PSMA was expressed in the vasculature 
of all types of lung carcinomas (Figure 3E,G,I) and their metasta-
ses (Figure 3F,H,J and Table 4). Overall, the vascular expression of 
PSMA was highest in the lung cancer BMs (Figure 3F,H,J) and low-
est in the melanoma BMs (Figure 3B,D), while the breast cancer 
BMs expressed moderate levels of PSMA (Figure 3A,C) as judged 
by visual evaluation. We then compared PSMA expression in the 
primary lung carcinomas and their BMs from the same patients 
(n = 52). In addition to the vascular expression of PSMA, the pri-
mary lung carcinomas (Figure 4A,C) and their corresponding met-
astatic lesions (Figure 4B,D) also expressed PSMA in the tumour 
cells. PSMA expression in the vasculature of the primary lung car-
cinomas and their metastatic lesions had no significant associa-
tion with various clinical factors (histopathological staging, age or 
gender) (Table 5). As smoking is one of the major causative factors 
in lung tumours, patients were divided into three categories based 
on their smoking history: (a) no prior smoking, (b) stopped smok-
ing and (c) still a smoker. No association between smoking and ei-
ther the vascular or the cellular expression of PSMA was detected 
in primary lung carcinomas or their BMs (Table 5).
3.4 | Tumour cell expression of PSMA is higher in 
secondary than in primary brain tumours
The tumour cell expression of PSMA varied substantially amongst 
the tumour types. When we compared PSMA expression between 
BMs of different origin, PSMA expression in tumour cells was 
higher in the BMs of lung and breast carcinoma than in melanoma 
BMs (Figure 5A-C). The cellular expression of PSMA was very 
low in gliomas (Figure 5D), which is consistent with the Ivy GAP 
data set results (Figure 2B). In addition, tumour cell expression of 
PSMA in the lung carcinomas and their metastatic lesions did not 
associate with any clinical or molecular pathological parameters 
(Table 5).
TA B L E  4   Histological classification of PSMA-positive tumours
Tumour  
Tumour histology
Adenocarcinoma Neuroendocrine SCC SCLC Others
Lung carcinomas Vascular 47.5% (19/40) 50% (1/2) 57.1% (4/7) 50% (2/4) 50% (1/2)
Tumour cells 62.5% (25/40) 50% (1/2) 85.7% (6/7) 50% (2/4) 100% (2/2)
Lung BMs Vascular 54.8% (23/42) 100% (2/2) 83.3% (5/6) 100% (4/4) 100% (2/2)
Tumour cells 71.4% (30/42) 100% (2/2) 100% (6/6) 100% (4/4) 100% (2/2)
Abbreviations: BM, brain metastases; PSMA, prostate-specific membrane antigen; SCC, squamous cell carcinomas; SCLC, small-cell lung carcinomas.
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3.5 | Vascular PSMA expression in primary 
lung carcinomas was associated with significantly 
accelerated metastatic dissemination into brain
The overall survival data were known for 55 lung carcinoma patients. 
The vascular PSMA expression in the primary lung carcinomas was 
associated with a tendency towards decreased overall survival 
(Mantel-Cox P = 0.092/Breslow P = 0.051) (Table 6, Figure 6A), 
whereas no association of PSMA expression in the tumour cells with 
the overall survival was observed (Mantel-Cox P = 0.583/Breslow 
P = 0.33) (Figure 6B). In addition, PSMA expression either in the 
tumour vasculature or in tumour cells did not associate with the 
progression-free survival (Table 6). Our patient cohort consisted of 
52 matched primary lung carcinomas and their corresponding BMs. 
F I G U R E  4   PSMA expression in the 
paired primary lung cancers and brain 
metastases from the same patient. A 
and B, PSMA expression in matched lung 
adenocarcinoma and brain metastasis. 
C and D, PSMA expression in matched 
lung squamous cell carcinoma and 
brain metastasis. Both the primary and 
metastatic tumour vasculature showed 
positivity for PSMA. Scale bar = 100 μm. 
PSMA, prostate-specific membrane 
antigen
TA B L E  5   Clinicopathologic features of the primary lung carcinomas and their brain metastases
Pathological parameter  Features
Primary lung carcinomas Lung brain metastasis
PSMA
Total
P-value
chi-square
PSMA
Total
P-value
chi-square+ − + −
Pathological staging I-II Vascular 15 18 33 .50 20 13 33 .57
III-IV 11 9 20 13 6 19
I-II Tumour cells 22 11 33 .90 24 9 33 .29
III-IV 13 7 20 17 2 19
Gender Male Vascular 14 15 29 .90 18 11 29 .72
Female 13 13 26 18 9 27
Male Tumour cells 20 9 29 .56 22 7 29 .61
Female 16 10 26 22 5 27
Age Min Vascular 38 43 Median .57 38 43 Median .19
Max 77 71 60a /57b  73 71 58a /62b 
Min Tumour cells 38 43 Median .93 38 43 Median .13
Max 77 71 59a /56b  73 71 58a /63b 
Smoking 0-1c  Vascular 10 10 20 .92 11 5 16 .83
2d  16 17 33 25 13 38
0-1c  Tumour cells 12 8 20 .62 12 4 16 .71
2d  22 11 33 31 7 38
Abbreviation: PSMA, prostate-specific membrane antigen.
(0)Quit smoking.
aPSMA-positive. 
bPSMA-negative. 
cNever smoked. 
dStill smoking(1), (2). 
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Primary tumours with PSMA-positive vasculature were associated 
with significantly faster metastatic dissemination to the brain com-
pared to tumours with PSMA-negative vasculature (Mantel-Cox 
P = 0.039/Breslow P = 0.005) (Table 7, Figure 6C). No association 
between PSMA expression in the tumour cells and accelerated 
metastatic dissemination was observed (Mantel-Cox P = 0.292/
Breslow P = 0.074) (Table 7, Figure 6D). The patients excluded from 
the analysis (n = 3) based on the diagnosis of the metastasis prior to 
the primary tumour detection still showed accelerated metastatic 
dissemination to the brain only if the vasculature was PSMA-positive 
(Mantel-Cox P = 0.012/Breslow P = 0.009) (Table S1, Figure S3A) 
but not the tumour cells (Mantel-Cox P = 0.135/Breslow P = 0.046) 
(Table S1, Figure S3B).
4  | DISCUSSION
In this report, we studied the expression of PSMA in large cohorts 
of primary and secondary brain tumours, using both traditional clini-
cal and molecular pathological methods. PSMA expression has been 
reported previously in gliomas,15 breast BMs20,21 and primary lung 
carcinomas22 but with a very limited number of patients. Our study 
spans across diverse tumour types with a large set of patient sam-
ples including gliomas (n = 371) and BM of tumours that commonly 
metastasize to the brain such as breast BMs (n = 18), melanoma 
BMs (n = 19) and lung BMs (n = 52, with matched primary lung car-
cinomas). We assessed PSMA expression at the protein level using 
tumour TMA and associated it with various clinical and molecular 
pathological parameters following the WHO 2016 guidelines for 
the classification of tumours of the central nervous system. We also 
took advantage of the cancer genome databases such as the TCGA 
(n = 567) and Ivy GAP (n = 10) to assess PSMA expression at the 
RNA level.
Our results show that PSMA expression was highest in the vas-
culature of glioblastomas especially in the proliferating hyperplastic 
microvasculature, one of the key angiogenic and histopathological 
traits of glioblastomas. This result is in agreement with an earlier 
study that consisted of 14 glioma and 5 glioblastoma specimens.15 
The study by Nomura et al15 showed moderate PSMA expression 
in grade I pilocytic astrocytomas (5 patients) and high expression 
in grade IV glioblastomas (GBM—5 patients), while grade II diffuse 
(4 patients) and grade III anaplastic (5 patients) astrocytomas were 
negative. The discrepancy between our study and Nomura et al15 
may be explained by the relatively small number of patients in each 
glioma grade in the Nomura study. They also pointed out that the 
variability of PSMA staining (both vascular and tumour cells) within 
gliomas needs to be explored in larger scale studies, which we have 
now addressed here.
F I G U R E  5   PSMA expression in 
the tumour cells varied between the 
tumour types. Amongst the primary 
and secondary brain tumours, the brain 
metastases of breast (A) and the lung 
(B) carcinomas showed the highest 
expression whereas the melanoma 
BMs (C) and glioblastomas (D) showed 
negligible expression of PSMA in the 
tumour cells. Scale bar = 100 μm. BM, 
brain metastases. PSMA, prostate-specific 
membrane antigen
TA B L E  6   Overall survival and progression-free survival based on PSMA expression
Tumour Features Function
PSMA (+)
Total/censored
PSMA (−)
Total/censored
Total
Total/censored
P-value
Log-rank/Breslow
Primary lung 
carcinomas
Vascular OS 27/3 28/4 55/7 .09/.05
PFS 27/18 28/16 55/34 .88/.80
Tumour cells OS 36/4 19/3 55/7 .58/.33
PFS 36/23 19/11 55/34 .83/.79
Lung BMs Vascular OS 36/8 20/1 56/9 .03/.01
PFS 36/23 20/11 56/34 .26/.24
Tumour cells OS 44/9 12/0 56/9 .13/.03
PFS 44/26 12/8 56/34 .84/.67
Abbreviations: BMs, brain metastases; OS, overall survival; PFS, progression-free survival; PSMA, prostate-specific membrane antigen.
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Microvascular hyperplasia is characterized by tufted micro-ag-
gregates, neovascular bodies with abundant and swiftly dividing 
endothelial cells, and inadequate pericyte/smooth muscle cell cover-
age. Microvascular hyperplasia, an essential feature associated with 
the tumour aggressiveness, is a potent predictor of poor prognosis.23 
Our TMA results corroborated with the results we obtained using 
the Ivy GAP data set. The significance of the Ivy GAP project is the 
use of laser microdissection to sample individual anatomic structures 
of the tumour followed by RNA sequencing. This results in struc-
ture-specific gene expression signatures, unlike the conventional tu-
mour RNA sequencing in which all different anatomic structures and 
cell types are pooled together. We also show that integrin β1 (ITGB1) 
is up-regulated in the PM. This is in concordance with the previous 
experimental report that showed PSMA-dependent increase in in-
tegrin β1-mediated signal transduction in a laminin-specific manner 
to regulate angiogenic endothelial adhesion and invasion.16 It has 
been reported that the vascular expression of PSMA in squamous 
cell carcinoma of the oral cavity is associated with poor prognosis.24 
In accordance with this, we show that vascular PSMA expression in 
gliomas associates with poor overall survival.
There are ample studies utilizing PSMA-based imaging agents 
for tumour detection in prostate cancer,25-32 high-grade glio-
mas33-37 and lung BMs,34 as well as in follicular thyroid adenoma,38 
metastatic renal cell carcinoma39 and melanoma and small-cell 
lung cancer (SCLC) xenografts in vivo.40 However, recent reports 
showed that the cerebral radionecrotic uptake41 or stroke42 re-
sulted in false-positive diagnoses of cerebral metastases based on 
PSMA/CT uptake as limitation of the PSMA-based diagnostic gli-
oma imaging. A single-arm phase II study where PSMA-recognizing 
antibody-drug conjugate (ADC) was used in progressive GBM pa-
tients (n = 6) following prior treatment with radiation, temozolo-
mide and bevacizumab showed no demonstrable activity in these 
F I G U R E  6   Association of PSMA 
expression with patient survival. A, The 
overall survival of the lung cancer patients 
(n = 55) whose tumours expressed PSMA 
in the vasculature (Mantel-Cox P = 0.092/
Breslow P = 0.051). B, The overall survival 
of the lung cancer patients (n = 55) with 
PSMA expression in tumour cells (Mantel-
Cox P = 0.583/Breslow P = 0.051). C, 
Primary lung carcinomas with vascular 
PSMA expression were associated with 
significantly accelerated rate of metastatic 
dissemination to brain (n = 52, Mantel-
Cox P = 0.039/Breslow P = 0.005). D, 
No significant association between 
brain metastases occurrence and PSMA 
expression in tumour cells was detected 
(n = 52, Mantel-Cox P = 0.292/Breslow 
P = 0.074). PSMA, prostate-specific 
membrane antigen
TA B L E  7   Time to metastatic dissemination from the primary tumour to the brain (n = 52)
Tumour Features
PSMA (+)
Total/censored
PSMA (−)
Total/censored
Total
Total/censored
P-Value
Log-rank/Breslow
Primary lung tumour Vascular 26/0 26/0 52/0 0.039/0.005
Tumour cells 34/0 18/0 52/0 0.292/0.074
Abbreviation: PSMA, prostate-specific membrane antigen.
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patients (NCT01856933). This was likely because of the minimal 
expression of the PSMA target and associated with dose-limiting 
toxicity.43 In our study, the vascular expression of PSMA was ob-
served in about 1/3 of glioblastomas. It thus raises a question of 
whether PSMA-based targeting agents could be used in these pa-
tients after patient stratification.
In addition to the glioma samples, we screened PSMA expression 
in the BMs of lung and breast cancers and melanomas. Even though 
PSMA expression has been reported earlier in breast cancer BM,15,34 
we show that PSMA expression associates with the accelerated met-
astatic dissemination to the brain only when it is expressed by the 
vasculature of primary tumours and not by the tumour cells. The 
tendency towards decreased overall survival of patients express-
ing PSMA in the vasculature of their lung tumours may be used as a 
prognostic factor but needs to be further validated in a larger data 
set of patient samples. Future studies with a larger cohort of patient 
material and mechanisms of how PSMA in the tumour endothelial 
cells accelerates metastatic dissemination to brain would provide 
novel information about PSMA role in metastatic dissemination.
Prostate-specific membrane antigen expression in the PM of glio-
blastoma near the CP is most likely a result of the hypoxia-induced 
angiogenesis. However, the vascular expression in primary lung neo-
plasm leading to accelerated metastatic dissemination has not been 
described earlier. Interestingly, a very recent preclinical study of a simi-
lar protein to PSMA, the prostate-specific antigen (PSA), could provide 
some clues on the molecular mechanism responsible for the acceler-
ated metastasis.44 In this study, the authors show how PSA activates 
the vascular endothelial growth factor C (via a proteolytic cleavage) 
which in turn promotes a pro-metastatic lymph/angiogenic niche.
In conclusion, we report that PSMA/FOLH1 expression in the 
vasculature leads to poor patient outcome using large patient data 
sets as well as the genomic data sets. In the future, it will be interest-
ing to see whether PSMA could be used as a diagnostic biomarker to 
detect and/or anticipate metastatic dissemination to the brain.
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